Literature DB >> 24477460

Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society.

Marc G Blainey1.   

Abstract

Santo Daime, a Brazilian religion organized around a potent psychoactive beverage called ayahuasca, is now being practiced across Europe and North America. Deeming ayahuasca a dangerous "hallucinogen," most Western governments prosecute people who participate in Santo Daime. On the contrary, members of Santo Daime (called "daimistas") consider ayahuasca a medicinal sacrament (or "entheogen"). Empirical studies corroborate daimistas' claim that entheogens are benign and can be beneficial when employed in controlled contexts. Following from anthropology's goal of rendering different cultural logics as mutually explicable, this article intercedes in a misunderstanding between policies of prohibition and an emergent subculture of entheogenic therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24477460     DOI: 10.1007/s10943-014-9826-2

Source DB:  PubMed          Journal:  J Relig Health        ISSN: 0022-4197


  26 in total

1.  Keeping the lid on: a century of drug regulation and control.

Authors:  Joseph Spillane; William B McAllister
Journal:  Drug Alcohol Depend       Date:  2003-06-05       Impact factor: 4.492

2.  Statement on ayahuasca.

Authors:  Brian T Anderson; Beatriz C Labate; Matthew Meyer; Kenneth W Tupper; Paulo C R Barbosa; Charles S Grob; Andrew Dawson; Dennis McKenna
Journal:  Int J Drug Policy       Date:  2012-03-27

Review 3.  Health status of ayahuasca users.

Authors:  Paulo Cesar Ribeiro Barbosa; Suely Mizumoto; Michael P Bogenschutz; Rick J Strassman
Journal:  Drug Test Anal       Date:  2012-07-04       Impact factor: 3.345

4.  Assessment of addiction severity among ritual users of ayahuasca.

Authors:  Josep Maria Fábregas; Débora González; Sabela Fondevila; Marta Cutchet; Xavier Fernández; Paulo César Ribeiro Barbosa; Miguel Ángel Alcázar-Córcoles; Manel J Barbanoj; Jordi Riba; José Carlos Bouso
Journal:  Drug Alcohol Depend       Date:  2010-06-15       Impact factor: 4.492

5.  Can psychedelics have a role in psychiatry once again?

Authors:  Ben Sessa
Journal:  Br J Psychiatry       Date:  2005-06       Impact factor: 9.319

6.  Consumption of ayahuasca by children and pregnant women: medical controversies and religious perspectives.

Authors:  Beatriz Caiuby Labate
Journal:  J Psychoactive Drugs       Date:  2011 Jan-Mar

Review 7.  Hallucinogen persisting perception disorder: what do we know after 50 years?

Authors:  John H Halpern; Harrison G Pope
Journal:  Drug Alcohol Depend       Date:  2003-03-01       Impact factor: 4.492

8.  Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.

Authors:  John H Halpern; Andrea R Sherwood; Torsten Passie; Kimberly C Blackwell; A James Ruttenber
Journal:  Med Sci Monit       Date:  2008-08

9.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

10.  LSD therapy in Dutch psychiatry: changing socio-political settings and medical sets.

Authors:  Stephen Snelders; Charles Kaplan
Journal:  Med Hist       Date:  2002-04       Impact factor: 1.419

View more
  3 in total

1.  Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Authors:  Benjamin J Malcolm; Kelly C Lee
Journal:  Ment Health Clin       Date:  2018-03-23

2.  Human rights, public health and medicinal cannabis use.

Authors:  Melissa Bone; Toby Seddon
Journal:  Crit Public Health       Date:  2015-11-16

Review 3.  Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.

Authors:  Jonathan Hamill; Jaime Hallak; Serdar M Dursun; Glen Baker
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.